AU2017272608B2 - Methods for predicting therapeutic benefit of anti-CD19 therapy in patients - Google Patents
Methods for predicting therapeutic benefit of anti-CD19 therapy in patients Download PDFInfo
- Publication number
- AU2017272608B2 AU2017272608B2 AU2017272608A AU2017272608A AU2017272608B2 AU 2017272608 B2 AU2017272608 B2 AU 2017272608B2 AU 2017272608 A AU2017272608 A AU 2017272608A AU 2017272608 A AU2017272608 A AU 2017272608A AU 2017272608 B2 AU2017272608 B2 AU 2017272608B2
- Authority
- AU
- Australia
- Prior art keywords
- lymphoma
- cells
- hodgkin
- ser
- peripheral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| EP16171885.3 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017272608A1 AU2017272608A1 (en) | 2018-12-06 |
| AU2017272608B2 true AU2017272608B2 (en) | 2023-08-10 |
Family
ID=56116221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017272608A Active AU2017272608B2 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-CD19 therapy in patients |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (OSRAM) |
| EP (2) | EP3465214B1 (OSRAM) |
| JP (2) | JP7066639B2 (OSRAM) |
| KR (1) | KR102416144B1 (OSRAM) |
| CN (2) | CN115932265A (OSRAM) |
| AU (1) | AU2017272608B2 (OSRAM) |
| BR (1) | BR112018074603A2 (OSRAM) |
| CY (1) | CY1124768T1 (OSRAM) |
| DK (2) | DK3916392T3 (OSRAM) |
| EA (1) | EA201892542A1 (OSRAM) |
| ES (2) | ES2878156T3 (OSRAM) |
| FI (1) | FI3916392T3 (OSRAM) |
| HR (2) | HRP20210938T1 (OSRAM) |
| HU (2) | HUE054860T2 (OSRAM) |
| IL (1) | IL263103B2 (OSRAM) |
| LT (2) | LT3916392T (OSRAM) |
| MA (2) | MA45124B1 (OSRAM) |
| MD (2) | MD3465214T2 (OSRAM) |
| MX (2) | MX388502B (OSRAM) |
| PL (2) | PL3465214T3 (OSRAM) |
| PT (2) | PT3916392T (OSRAM) |
| RS (2) | RS62155B1 (OSRAM) |
| SG (2) | SG11201810159TA (OSRAM) |
| SI (2) | SI3916392T1 (OSRAM) |
| SM (2) | SMT202400204T1 (OSRAM) |
| WO (1) | WO2017207574A1 (OSRAM) |
| ZA (2) | ZA201808647B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| LT3532098T (lt) | 2016-10-28 | 2021-06-25 | Morphosys Ag | Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| MA55794A (fr) * | 2019-05-03 | 2022-03-09 | Morphosys Ag | Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk |
| KR20220103969A (ko) * | 2019-10-31 | 2022-07-25 | 모르포시스 아게 | 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법 |
| CN114786723A (zh) * | 2019-10-31 | 2022-07-22 | 莫佛塞斯公司 | 序贯抗cd19疗法 |
| BR112023010885A2 (pt) * | 2020-12-04 | 2023-10-03 | Incyte Corp | Terapia de combinação de anti-cd19 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101063278B1 (ko) | 1998-08-11 | 2011-09-07 | 바이오겐 아이덱 인크. | Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제 |
| WO2002068414A2 (en) | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| PT1966245E (pt) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| ATE501436T1 (de) | 2006-09-13 | 2011-03-15 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| LT2176298T (lt) | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| SG190254A1 (en) | 2010-11-15 | 2013-06-28 | Medimmune Llc | Combination therapy for b cell lymphomas |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| KR20200058583A (ko) | 2011-08-16 | 2020-05-27 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| PL2744826T3 (pl) * | 2011-08-16 | 2022-05-30 | Morphosys Ag | Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny |
| WO2013090478A1 (en) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Predicting responsiveness to antibody maintenance therapy |
| EP3110445A4 (en) * | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| CN106794231A (zh) * | 2014-06-16 | 2017-05-31 | 赞科股份有限公司 | 用于慢性淋巴细胞性白血病（cll）的治疗 |
| WO2016005548A1 (en) | 2014-07-11 | 2016-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
-
2017
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt active Search and Examination
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| WOYACH J A ET AL: "A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, vol. 124, DOI: 10.1182/BLOOD-2014-08-593269 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220283166A1 (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| IL295023A (en) | Antibodies and fusion proteins that bind to ccr8 and their uses | |
| JP2023112043A (ja) | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 | |
| US20220242952A1 (en) | Anti-cd19 therapy in patients having a limited number of nk cells | |
| HK40065007B (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| HK40065007A (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| NZ788788A (en) | Methods for predicting therapeutic benefit of anti-CD19 therapy in patients | |
| EA040320B1 (ru) | Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19 | |
| HK40002753B (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| HK40002753A (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| KR20220085796A (ko) | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: INCYTE CORPORATION Free format text: FORMER OWNER(S): MORPHOSYS AG |